Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:COS CVE:PAS NYSEAMERICAN:SYN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOSCanadian Oil SandsC$0.00C$5.61▼C$13.87N/AN/A2.19 million shsN/APASPascal BiosciencesC$0.02-25.0%C$0.02C$0.02▼C$0.10C$984K1.5152,289 shs4,000 shsSYNSynthetic Biologics$0.00$0.97▼$4.56$16.16M1.38197,338 shs57,700 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePASPascal Biosciences0.00%0.00%0.00%0.00%0.00%SYNSynthetic Biologics0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOSCanadian Oil SandsC$0.00C$5.61▼C$13.87N/AN/A2.19 million shsN/APASPascal BiosciencesC$0.02-25.0%C$0.02C$0.02▼C$0.10C$984K1.5152,289 shs4,000 shsSYNSynthetic Biologics$0.00$0.97▼$4.56$16.16M1.38197,338 shs57,700 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePASPascal Biosciences0.00%0.00%0.00%0.00%0.00%SYNSynthetic Biologics0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOSCanadian Oil Sands 0.00N/AN/AN/APASPascal Biosciences 0.00N/AN/AN/ASYNSynthetic Biologics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOSCanadian Oil SandsN/AN/AN/AN/AN/AN/APASPascal BiosciencesN/AN/AC$0.00 per share55.00C($0.02) per shareN/ASYNSynthetic BiologicsN/AN/AN/AN/A$4.95 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOSCanadian Oil SandsN/AN/AN/AN/AN/AN/AN/AN/AN/APASPascal BiosciencesN/A-C$0.01N/AN/AN/AN/AN/A-340.40%N/ASYNSynthetic Biologics-$14.27M-$1.21N/AN/AN/AN/A-26.14%-22.74%N/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCOSCanadian Oil SandsN/AN/AN/AN/AN/APASPascal BiosciencesN/AN/AN/AN/AN/ASYNSynthetic BiologicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOSCanadian Oil SandsN/AN/AN/APASPascal Biosciences882.790.030.17SYNSynthetic BiologicsN/A4.144.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOSCanadian Oil SandsN/APASPascal BiosciencesN/ASYNSynthetic Biologics74.38%Insider OwnershipCompanyInsider OwnershipCOSCanadian Oil SandsN/APASPascal Biosciences15.43%SYNSynthetic Biologics2.15%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOSCanadian Oil Sands147,000N/AN/ANot OptionablePASPascal Biosciences665.59 millionN/ANot OptionableSYNSynthetic Biologics1615.84 million15.50 millionNot OptionableCOS, HEMO, PAS, and SYN HeadlinesRecent News About These CompaniesComputational design drives new generation of synthetic promotersMarch 27, 2026 | drugtargetreview.comDGene Synthesis Market Comprehensive Industry Analysis, Trends, and Future OutlookFebruary 25, 2026 | pharmiweb.comP6 ways biologics is advancing in spineFebruary 19, 2026 | beckersspine.comBStopping Biologics Before Surgery May Raise Flare Risk in RAJanuary 27, 2026 | rheumatologyadvisor.comRStudy Shows NanoFuse(R) Superiority: Why Bioactive Glass-DBM Composites Outperform DBM and Bioactive Glass AloneJanuary 26, 2026 | marketwatch.comMTF Biologics and Kolosis BIO Launch New Solution for Orthopedic and Spinal Surgeries: Summit Matrix™January 15, 2026 | uk.finance.yahoo.comMTF Biologics and Kolosis BIO Launch New Solution for Orthopedic and Spinal Surgeries: Summit Matrix(TM)January 15, 2026 | marketwatch.comAsimov and AGC Biologics Team Up to Provide a Cost-Effective, Simplified, and Secure Manufacturing Approach for Viral Vector ProductionJanuary 13, 2026 | pharmiweb.comP4 orthobiologics updatesDecember 18, 2025 | beckersspine.comBExposure to Some DMARDs in Fathers-to-Be Tied to Birth RisksDecember 2, 2025 | medscape.comMRelapse in Juvenile Idiopathic Arthritis After Stopping DMARDs: Key Factors FoundDecember 1, 2025 | medscape.comMConstructive Bio and RxCelerate partner to develop biologic therapeutic candidatesNovember 19, 2025 | businessweekly.co.ukBRA Onset Age Doesn’t Affect Non-TNF Agents’ Infection RiskOctober 29, 2025 | medscape.comMAurora Spine Launches New Biologics PortfolioOctober 28, 2025 | markets.businessinsider.comWound Care Biologics Market Size Worth USD 11.22 Billion by 2034October 27, 2025 | finance.yahoo.comStudy assesses SI joint outcomes between surgeons, pain physiciansOctober 21, 2025 | beckersspine.comBActive Pharmaceutical Ingredients (API) Market worth $198.39 billion by 2030 with 6.6% CAGR | MarketsandMarkets™October 15, 2025 | finance.yahoo.comRheumatoid Arthritis Linked to Elevated Pneumonia Risk, Especially in Seropositive DiseaseOctober 1, 2025 | ajmc.comAProtein Expression Market to Hit USD 6.60 Billion by 2032 on Rising Biologics and Personalized Medicine Demand | S&S InsiderSeptember 26, 2025 | finance.yahoo.comFrom Synthetic Identities to Synthetic Receipts: The New Frontier of FraudJuly 17, 2025 | securityinfowatch.comSMedia Sentiment Over Time Top HeadlinesView All HeadlinesApple’s Agentic AI Plans Could Be Its Biggest Growth Story YetBy Sam Quirke | May 29, 2026Costco’s Strong Quarter Still Leaves Investors With a Valuation ProblemBy Dan Schmidt | May 30, 2026Navitas: NVIDIA’s AI Power Broker?By Jeffrey Neal Johnson | June 5, 2026Is Co-Diagnostics National Security’s Next Diagnostic Pick?By Jeffrey Neal Johnson | May 28, 2026Apple's Siri AI Was Finally Announced, So Why Is the Stock Tanking?By Sam Quirke | June 9, 2026COS, HEMO, PAS, and SYN Company DescriptionsCanadian Oil Sands TSE:COSConiagas Battery Metals Inc. is a Canadian junior mining company focused on nickel, copper and cobalt and platinum group metals in Québec. Coniagas' strategy is to create value for shareholders through the development of its mineral properties, with the intention to develop Coniagas into a critical metals supplier to the electric vehicle (EV) market. At its 100% owned Graal project near Saguenay, Quebec, Coniagas has conducted successful exploration involving geophysics as well as shallow drilling that hit mineralization in almost every hole. It has confirmed an open-pit deposit model at Graal along a 6 km strike length of high-grade nickel and copper with cobalt, platinum and palladium byproducts. The Company plans in the near-term to conduct additional drilling leading to the production of a Ni 43-101 resource report, metallurgical testing and consultations with First Nations.Pascal Biosciences CVE:PASC$0.02 -0.01 (-25.00%) As of 12/5/2022Pascal Biosciences Inc., a biotechnology company, engages in the research and development of products for the treatment of cancer, and for the improvement of the immune system. The company's development portfolio includes PAS-403, a mitosis inhibitor that blocks cell division for the treatment of glioblastoma and brain metastases originating from other cancers; and PAS-393, an immune-stimulatory cannabinoid designed to restore the immunogenicity of tumor cells with checkpoint inhibitor therapy for use in cancer treatment. It is also developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas; and cannabinoid therapeutic products for the treatment of COVID-19. The company has an exclusive license agreement with the University of Washington to develop a cannabinoid-based product for the treatment of glioblastoma multiforme and brain metastases; and a collaborative research agreement with SoRSE Technology Corporation to advance PAS-393 into clinical testing. Pascal Biosciences Inc. was incorporated in 2011 and is headquartered in Seattle, Washington.Synthetic Biologics NYSEAMERICAN:SYNSynthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate VMware: Broadcom's Second Biggest Business Set to Accelerate American Eagle’s Q1 Beat Leaves Investors With a Bigger Question The Netflix-Lionsgate Rumor Exposed a Bigger Shift in Media M&A Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
